| pubmed-article:10680843 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10680843 | lifeskim:mentions | umls-concept:C1519025 | lld:lifeskim |
| pubmed-article:10680843 | lifeskim:mentions | umls-concept:C0023621 | lld:lifeskim |
| pubmed-article:10680843 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:10680843 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:10680843 | lifeskim:mentions | umls-concept:C0003241 | lld:lifeskim |
| pubmed-article:10680843 | lifeskim:mentions | umls-concept:C1514562 | lld:lifeskim |
| pubmed-article:10680843 | lifeskim:mentions | umls-concept:C1883221 | lld:lifeskim |
| pubmed-article:10680843 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:10680843 | lifeskim:mentions | umls-concept:C1707391 | lld:lifeskim |
| pubmed-article:10680843 | lifeskim:mentions | umls-concept:C1883204 | lld:lifeskim |
| pubmed-article:10680843 | lifeskim:mentions | umls-concept:C1880389 | lld:lifeskim |
| pubmed-article:10680843 | lifeskim:mentions | umls-concept:C1514926 | lld:lifeskim |
| pubmed-article:10680843 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:10680843 | pubmed:dateCreated | 2000-3-16 | lld:pubmed |
| pubmed-article:10680843 | pubmed:abstractText | To generate T cell-specific retroviral vectors an scFv phage display library derived from immunized mice was selected for binding to the human T cell line Molt-4/8. The scFv cDNAs recovered from the selected phages were transiently expressed as an N-terminal fusion of the spleen necrosis virus (SNV) transmembrane protein (TM) subunit of the viral envelope protein (Env) in the cell line DSH-cxl, which packages the beta-galactosidase gene into SNV particles. Screening of supernatants from about 150 transfections resulted in the identification of 5 scFvs that mediated efficient transduction of Molt-4/8 cells. Using stable packaging cell lines vector preparations with titers greater than 10(4) EFU/ml on human T cells were obtained. The scFv 7A5 in particular was able to mediate selective transduction of human T cells with high efficiency. Titers of up to 106 EFU/ml were reached on Molt-4/8, Jurkat, and A301 cells, while titers on HeLa cells, TE671 cells, 293T cells, and HT1080 cells were below 102 EFU/ml. Transduction of stimulated primary human peripheral blood cells, which consisted mainly of T cells, was about fivefold more efficient than transduction of B cells. Western blot analysis of supernatant from the 7A5 packaging cells demonstrated incorporation of 7A5-TM into vector particles and indicated proteolytic processing of the coexpressed unmodified TM during particle formation. Binding of bacterially expressed 7A5-scFv to a panel of cell lines correlated well with the transduction results. These data provide the first proof of concept that a general approach can be taken to obtain scFvs able to mediate selective gene transfer into target cells. | lld:pubmed |
| pubmed-article:10680843 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10680843 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10680843 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10680843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10680843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10680843 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10680843 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10680843 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:10680843 | pubmed:issn | 1043-0342 | lld:pubmed |
| pubmed-article:10680843 | pubmed:author | pubmed-author:KurthRR | lld:pubmed |
| pubmed-article:10680843 | pubmed:author | pubmed-author:BuchholzC JCJ | lld:pubmed |
| pubmed-article:10680843 | pubmed:author | pubmed-author:BaierMM | lld:pubmed |
| pubmed-article:10680843 | pubmed:author | pubmed-author:DornburgRR | lld:pubmed |
| pubmed-article:10680843 | pubmed:author | pubmed-author:CichutekKK | lld:pubmed |
| pubmed-article:10680843 | pubmed:author | pubmed-author:ChuT HTH | lld:pubmed |
| pubmed-article:10680843 | pubmed:author | pubmed-author:StittLL | lld:pubmed |
| pubmed-article:10680843 | pubmed:author | pubmed-author:EngelstädterM... | lld:pubmed |
| pubmed-article:10680843 | pubmed:author | pubmed-author:BobkovaMM | lld:pubmed |
| pubmed-article:10680843 | pubmed:author | pubmed-author:HoltkampNN | lld:pubmed |
| pubmed-article:10680843 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10680843 | pubmed:day | 20 | lld:pubmed |
| pubmed-article:10680843 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:10680843 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10680843 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10680843 | pubmed:pagination | 293-303 | lld:pubmed |
| pubmed-article:10680843 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:meshHeading | pubmed-meshheading:10680843... | lld:pubmed |
| pubmed-article:10680843 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10680843 | pubmed:articleTitle | Targeting human T cells by retroviral vectors displaying antibody domains selected from a phage display library. | lld:pubmed |
| pubmed-article:10680843 | pubmed:affiliation | Department of Medical Biotechnology, Paul-Ehrlich-Institut, Langen, Germany. | lld:pubmed |
| pubmed-article:10680843 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10680843 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10680843 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10680843 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10680843 | lld:pubmed |
